Drugs /

interleukin-2

Back to Drugs List

Overview

NCI Definition [1]:
Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.

Clinical Trials

View Clinical Trials for interleukin-2

Interleukin-2 has been investigated in 28 clinical trials, of which 22 are open and 6 are closed. Of the trials investigating interleukin-2, 1 is early phase 1 (0 open), 13 are phase 1 (10 open), 8 are phase 1/phase 2 (7 open), and 6 are phase 2 (5 open).

EBV Positive, MS4A1 Expression, and Normal karyotype are the most frequent biomarker inclusion criteria for interleukin-2 clinical trials.

Melanoma, B-cell non-hodgkin lymphoma, and acute myeloid leukemia are the most common diseases being investigated in interleukin-2 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Interleukin-2
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Interleukin-2
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating interleukin-2 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
epidermal thymocyte activating factor, etaf, il-2, il2, il2 protein, t-cell growth factor, t cell growth factor, ro-236019, lymphocyte mitogenic factor, interleukin 2, interleukin ii, interleukin 2 precursor, tsf, thymocyte stimulating factor, tcgf
NCIT ID [1]:
C20507

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.